Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Ocular Therapeutix Inc (OCUL) USD0.0001

Sell:$4.05 Buy:$4.06 Change: $0.06 (1.50%)
Market closed |  Prices as at close on 12 December 2019 | Switch to live prices |
Sell:$4.05
Buy:$4.06
Change: $0.06 (1.50%)
Market closed |  Prices as at close on 12 December 2019 | Switch to live prices |
Sell:$4.05
Buy:$4.06
Change: $0.06 (1.50%)
Market closed |  Prices as at close on 12 December 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.

Contact details

Address:
24 Crosby Dr
BEDFORD
01730-1402
United States
Telephone:
+1 (781) 8953235
Website:
www.ocutx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
OCUL
ISIN:
US67576A1007
Market cap:
$196.65 million
Shares in issue:
48.08 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Antony Mattessich
    President, Chief Executive Officer, Director
  • Donald Notman
    Chief Financial Officer
  • Patricia Kitchen
    Chief Operations Officer
  • Daniel Bollag
    Senior Vice President- Regulatory Affairs and Quality
  • Kevin Hanley
    Senior Vice President - Technical Operations
  • Christopher White
    Senior Vice President, Head of Business and Corporate Development
  • Michael Goldstein
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.